title: Myeloprolipherative disorder type chronic myeloid leukemia--eosinophilic form.
abstract: Chronic eosinophilic leukemia (CEL) is a very rare form of leucemia in the western world. Adequate response is seldomly achieved after treatment with corticosteroids, interferon-alfa (INF-alfa) and medications containing hydroxi-urea (Litalir). The study presents a patient with CEL with no initial therapeutic response to the use of corticosteroids, INF-alfa and hydroxy-urea, and with neither clinical nor hematological response. After setting a diagnosis of CEL, patient was ordinated Imatinib (Glivec tabbletes) in a daily dose of 200 mg. Two days afterwards there was an evident withdrawal of subjective and clinical symptoms of disease, and the complete blood count showed significant amendment.
authors.affiliation: Clinic for Oncology, Hematology and Radiotherapy, Department of Hematology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina' Policlinic for Blood Transfusion, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina. aidahem@yahoo.com
authors.forename: Aida
authors.initials: A
authors.lastname: Arnautovic-Custovic
authors.forename: Samira
authors.initials: S
authors.lastname: Hasic
authors.forename: Emina
authors.initials: E
authors.lastname: Kopic
authors.forename: Azra
authors.initials: A
authors.lastname: Jahic
authors.forename: Svetlana
authors.initials: S
authors.lastname: Jovic
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002908:Chronic Disease; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate